Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
100%
Heart Failure
59%
Biological Marker
51%
Creatinine
31%
Disease
24%
Cardiovascular Disease
23%
Chronic Kidney Failure
23%
Non Insulin Dependent Diabetes Mellitus
22%
Placebo
22%
Adverse Event
22%
Dapagliflozin
19%
Adverse Drug Reaction
19%
All Cause Mortality
18%
Brain Natriuretic Peptide
17%
Malignant Neoplasm
15%
Serelaxin
14%
Terminal Illness
14%
Rolofylline
13%
Head and Neck Cancer
12%
Primary Tumor
12%
Advanced Cancer
12%
Lung Cancer
12%
Clinical Trial
11%
Progression Free Survival
10%
Relaxin
9%
Second-Generation Antidepressant
9%
Fluoxetine
9%
Randomized Controlled Trial
9%
Event Free Survival
9%
Prevalence
8%
Adverse Outcome
8%
Recurrent Disease
8%
Cardiovascular Mortality
7%
Growth Differentiation Factor 15
7%
Disulfide
7%
Tolerability
7%
Comorbidity
7%
Metabolic Syndrome X
7%
Galectin 3
7%
Coronary Artery Disease
6%
Hospital Mortality
6%
Atrioventricular Septal Defect
6%
Rheumatoid Arthritis
6%
Paroxetine
6%
Alzheimer's Disease
6%
Drug Development
6%
Alanine Aminotransferase
6%
Oral Antidiabetic Agent
6%
Procalcitonin
6%
Sertraline
6%
Medicine and Dentistry
Heart Failure
43%
Acute Decompensated Heart Failure
35%
Maturity Onset Diabetes of the Young
31%
Kidney Function
26%
Health Care Cost
22%
Chronic Kidney Disease
21%
Biological Marker
21%
Dapagliflozin
19%
Quality of Life
17%
Radiation Therapy
17%
Creatinine
14%
Disease
14%
Cardiovascular Disease
14%
Sex Difference
12%
Blood Pressure
12%
Lung Transplantation
12%
Proton Therapy
12%
Observational Study
12%
Disease Management
12%
Copeptin
12%
Lung Cancer
12%
Health Technology
11%
Urinary System
11%
Hazard Ratio
11%
Cost-Effectiveness Analysis
11%
Cardiovascular System
10%
Photon Therapy
10%
Clinical Trial
9%
Primary Prevention
9%
Attitude
8%
Technology Assessment
8%
Systolic Blood Pressure
8%
Adverse Outcome
8%
Patient with Type 2 Diabetes
7%
Randomized Controlled Trial
7%
Meta-Analysis
7%
Clinical Decision Making
7%
Low Drug Dose
6%
Medicine
6%
Diagnosis
6%
Coronary Artery Disease
6%
Cumulative Incidence
6%
Diabetes
6%
Atrioventricular Septal Defect
6%
Life Expectancy
6%
Progression Free Survival
6%
Hospital Mortality
6%
Oral Antidiabetic Agent
6%
Impaired Glucose Tolerance
6%
Advanced Cancer
6%
Keyphrases
Acute Heart Failure
67%
Heart Failure
29%
Confidence Interval
18%
Type 2 Diabetes Mellitus (T2DM)
18%
Prognostic Value
16%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
15%
Patients with Heart Failure
15%
Heart Failure Patients
15%
Hazard Ratio
14%
Clinical Outcomes
14%
Rolofylline
13%
Competing Risks
13%
Serelaxin
13%
All-cause Mortality
12%
Net Monetary Benefit
12%
Patient Preference Trial
12%
Novel Biomarkers
12%
Blood Pressure
12%
Dapagliflozin
12%
Prospective Observational Study
12%
Galectin-3 (Gal-3)
12%
Comorbidity
12%
Preference Information
10%
Renal Function
10%
Netherlands
10%
Clinical Characteristics
10%
Chronic Kidney Disease
9%
Patient Preference
9%
Coaching
9%
Growth Differentiation factor-15 (GDF-15)
8%
Heart Failure Hospitalization
8%
Low Risk
8%
Adverse Outcomes
8%
Predictive Value
8%
Relaxin
8%
Cardiovascular Mortality
7%
Plasma Biomarkers
7%
Disulfide
7%
Clinical Trials
7%
Creatinine
7%
Mortality Risk
7%
Randomized Controlled Trial
7%
Type 2 Diabetic Patients
7%
Preference Elicitation
7%
Odds Ratio
7%
Response to Treatment
7%
Systolic Blood Pressure
6%
Treatment Effect
6%
Cardiovascular Disease Events
6%
Multi-criteria Model
6%
